Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series.

Rusen Cosar Necdet SutAlaattin OzenEbru TastekinSernaz TopalogluIrfan CicinDilek NurluTalar OzlerSeda DemirGokay Yıldız Eylül ŞenödeyiciMustafa Cem Uzal

Published in: Breast cancer (Dove Medical Press) (2022)

The HER2-enriched subgroup had the worst prognosis despite receiving targeted therapy. While the duration of DFS and OS had no significant difference between TNBC and Luminal A-B subgroups, HER2 enriched subgroup had significantly shorter survival when compared to any other subgroup. HER2-enriched subgroup had a 10-fold greater risk of death compared to the Luminal A subgroup.

Keyphrases

phase iii
machine learning
randomized controlled trial
deep learning
open label